Lee R Machado
High mobility group protein B1 is a predictor of poor survival in ovarian cancer
Machado, Lee R; Moseley, Paul M.; Moss, Robert; Deen, Suha; Nolan, Christopher C.; Spendlove, Ian; Ramage, Judith M.; Chan, Stephen Y.T.; Durrant, Lindy
Authors
Paul M. Moseley
Robert Moss
Suha Deen
Christopher C. Nolan
IAN SPENDLOVE IAN.SPENDLOVE@NOTTINGHAM.AC.UK
Associate Professor
JUDITH RAMAGE JUDITH.RAMAGE@NOTTINGHAM.AC.UK
Associate Professor
Stephen Y.T. Chan
Lindy Durrant
Abstract
High-mobility group protein B1 (HMGB1) has been implicated in numerous tumour types where expression regulates tumour cell growth and survival. We hypothesised that high HMGB1 expression in ovarian tumours would predict poor patient survival.
Using tissue microarrays of primary ovarian cancers combined with a comprehensive database of clinicopathological variables, the expression of HMGB1 was assessed by immunohistochemistry in two independent cohorts (n=194 and n=360) using a monoclonal antibody specific for HMGB1.
Kaplan-Meier analysis showed an association of HMGB1 expression with progression free survival in the primary cohort (p=0.023). In the validation cohort, expression was associated with overall survival (p=0.002). Low expression of HMGB1 was protective and in a multivariate model HMGB1 expression was shown to be an independent predictor of poor survival in ovarian cancer (p=0.006).
The role of HMGB1 in cancer is complex. As high levels of HMGB1 expression are likely to render ovarian cancer cells resistant to chemotherapy, therapies targeting the HMGB1 axis may be appropriate in the treatment of ovarian cancer patients
Citation
Machado, L. R., Moseley, P. M., Moss, R., Deen, S., Nolan, C. C., Spendlove, I., …Durrant, L. (2017). High mobility group protein B1 is a predictor of poor survival in ovarian cancer. Oncotarget, https://doi.org/10.18632/oncotarget.20538
Journal Article Type | Article |
---|---|
Acceptance Date | Aug 7, 2017 |
Publication Date | Aug 24, 2017 |
Deposit Date | Aug 31, 2017 |
Publicly Available Date | Aug 31, 2017 |
Journal | Oncotarget |
Electronic ISSN | 1949-2553 |
Publisher | Impact Journals |
Peer Reviewed | Peer Reviewed |
DOI | https://doi.org/10.18632/oncotarget.20538 |
Keywords | HMGB1, autophagy, ovarian cancer, prognostic, DAMP |
Public URL | https://nottingham-repository.worktribe.com/output/878788 |
Publisher URL | http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=20538&path[]=65471 |
Contract Date | Aug 31, 2017 |
Files
20538-294614-1-PB. Ramage.pdf
(2.4 Mb)
PDF
Copyright Statement
Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by/4.0
You might also like
Monoclonal antibodies targeting LecLex-related glycans with potent antitumor activity
(2015)
Journal Article
Molecular and structural basis for Lewis glycan recognition by a cancer-targeting antibody
(2020)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search